ImmunoRad: Stratified Phase II Trial of Image Guided Hypofractionated Radiotherapy With Concurrent Nelfinavir and Nivolumab in Advanced Melanoma, Lung Cancer, and Renal Cell Carcinoma

Trial Profile

ImmunoRad: Stratified Phase II Trial of Image Guided Hypofractionated Radiotherapy With Concurrent Nelfinavir and Nivolumab in Advanced Melanoma, Lung Cancer, and Renal Cell Carcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Nelfinavir (Primary) ; Nivolumab (Primary)
  • Indications Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 19 May 2017 Planned initiation date changed from 1 Apr 2017 to 1 Jul 2017.
    • 13 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top